Dilated Cardiomyopathy

Slide 1 · Dilated Cardiomyopathy

Intrinsic myocardial dysfunction with progressive dilation and impaired systolic contraction

Etiology • pathogenesis • morphology • clinical consequences

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Distinguish primary DCM from secondary causes of a dilated, poorly contracting heart.

Explain genetic, inflammatory, toxic, metabolic, and pregnancy-associated pathways.

Connect chamber dilation and microscopic remodeling with heart failure and embolic risk.

Apply gross morphology and clinical clues to differential diagnosis.

Slide 3 · The defining DCM phenotype

Progressive cardiac chamber dilation is accompanied by loss of effective contraction.

Systolic dysfunction is the principal functional abnormality.

Myocardial hypertrophy commonly coexists despite the dilated, flabby appearance.

DCM describes a convergent phenotype—not a single etiologic disorder.

Slide 4 · From myocyte dysfunction to a dilated heart

Myocyte dysfunction

Reduced force generation

Systolic impairment

Progressive dilation

A shared anatomic and functional endpoint can arise from many different initiating injuries.

Slide 5 · The three major cardiomyopathy patterns

Dilated

Enlarged chamber cavities and ineffective contraction. Principal dysfunction: Systolic.

Hypertrophic

Marked muscular hypertrophy with impaired ventricular compliance. Predominantly diastolic dysfunction.

Restrictive

Reduced ventricular compliance restricts filling; Chambers are often not dilated.

Slide 6 · DCM among cardiomyopathy patterns

~90%

DCM as the most common major cardiomyopathy pattern.

The estimate concerns the textbook’s three-pattern categorization.

Classification by phenotype does not establish an etiologic cause.

Overlap in clinical manifestations is possible.

Slide 7 · Cardiomyopathy versus secondary myocardial dysfunction

Intrinsic cardiomyopathy

Conditions that can mimic it

Clinical implication

Primary myocardial disease

Coronary artery disease / ischemic injury

Assess whether ischemia explains dysfunction.

A DCM phenotype may be idiopathic or specific

Hypertension / valvular disorders

Determine whether loading or valve disease is causal.

Potential genetic or acquired myocardial insult

Congenital heart disease

Evaluate structural disease before labeling primary DCM.

Slide 8 · The diagnostic category requires etiologic exclusion

Poor contraction and dilation are nonspecific features of an end-stage failing heart.

Primary DCM is considered after major ischemic, valvular, hypertensive, and congenital explanations are excluded.

An idiopathic designation means that a specific cause has not been identified—not that none exists.

Slide 9 · Functional impairment and clinical expression

Systolic dysfunction

Reduced effective forward output

Compensatory remodeling

Heart failure symptoms

Remodeling may initially sustain circulation but does not restore normal contractile function.

Slide 10 · Functional reference point: Systolic dysfunction

<40%

The Robbins functional-pattern table associates DCM with reduced LV ejection fraction.

This tabular pattern is not a stand-alone diagnostic criterion.

LV ejection fraction must be interpreted alongside structural findings.

Competing causes of low ejection fraction require evaluation.

Slide 11 · Severely advanced DCM

<25%

Typical ejection fraction in end-stage DCM.

This is a description of end-stage disease, not all DCM.

Poor global contractility explains impaired cardiac performance.

Clinical severity can exceed what gross histology predicts.

Slide 12 · Convergent etiologic pathways

Inherited

Variants affecting myocyte force generation, transmission, or cellular integrity.

Inflammatory / toxic

Myocarditis, alcohol, cardiotoxic exposures, and chemotherapy-associated injury.

Physiologic / metabolic

Peripartum injury, iron excess, tachycardia, endocrine or catecholamine stress.

Slide 13 · Familial DCM is increasingly recognized

Up to 50%

A familial contribution in as many as half of cases.

Family history can guide suspicion but is not universally evident.

Incomplete penetrance limits inference from unaffected relatives.

Multifactorial progression complicates genotype–phenotype prediction.

Slide 14 · Genes converge on myocyte structural integrity

DCM-associated variants involve proteins at the cytoskeleton, sarcolemma, and nuclear envelope.

The functions of affected proteins are diverse; Several cellular routes lead to impaired contraction.

A single gross phenotype does not imply a single molecular mechanism.

Slide 15 · Structural protein defects: Mechanical consequences

Cytoskeletal / envelope defect

Disordered myocyte integrity

Inefficient force transfer

Contractile dysfunction

Pathogenic pathways may involve impaired force generation, force transmission, or cellular signaling.

Slide 16 · Titin: The sarcomeric molecular spring

TTN encodes titin, a giant protein spanning the sarcomere from Z band toward M band.

Titin limits passive stretching and contributes to muscle elasticity.

Titin abnormalities can undermine normal mechanics of the contractile apparatus.

Slide 17 · TTN truncations in DCM

10–20%

Approximate proportion of all DCM cases attributed to TTN truncation mutations.

TTN is identified as the most common genetic cause figure caption.

The variant class matters: A TTN sequence change alone is not diagnostic.

Interpretation requires clinical and familial context.

Slide 18 · Genetic structures implicated in DCM

Sarcomere

Titin contributes passive elasticity and mechanics across the sarcomere.

Cell membrane / cytoskeleton

Dystrophin links intracellular cytoskeleton to extracellular matrix.

Nuclear envelope

Lamin A/C contributes to nuclear structural organization.

Slide 19 · Dystrophin-associated cardiomyopathy

Dystrophin couples the myocyte cytoskeleton to the extracellular matrix.

Dystrophin gene defects can accompany Duchenne or Becker muscular dystrophy.

Some dystrophin mutations manifest primarily as dilated cardiomyopathy.

Slide 20 · Lamin A/C and the nuclear envelope

Nuclear-envelope protein genes, including lamin A/C, are represented among DCM-associated genes.

The nuclear envelope is one example of a non-sarcomeric cellular compartment implicated in disease.

Mechanical integrity and intracellular signaling abnormalities may converge on myocyte dysfunction.

Slide 21 · Inheritance patterns in familial DCM

Inheritance

Relative frequency

Teaching implication

Autosomal dominant

Predominant

Variable penetrance within families.

X-linked

Less common

Dystrophin-associated disease is an example.

Autosomal recessive

Less common

Recessive variants are among recognized causes.

Mitochondrial

Less common

Defects can impair oxidative phosphorylation.

Slide 22 · Variable penetrance complicates family assessment

Identical familial risk does not imply identical clinical expression.

Variable penetrance suggests influences beyond the causal genetic variant.

A clinically unaffected relative cannot, by itself, exclude a familial contribution.

Slide 23 · Mitochondrial dysfunction as a DCM pathway

Mitochondrial gene defects

Impaired oxidative phosphorylation

Reduced cellular energy supply

Myocyte dysfunction

Selected mitochondrial gene deletions with cardiomyopathy, often presenting in pediatric patients.

Slide 24 · Fatty acid β-oxidation disorders

Some inherited DCM phenotypes involve genes encoding enzymes for fatty-acid β-oxidation.

Impaired metabolic substrate use can compromise the energy-dependent myocardium.

Metabolic causes are especially relevant in the early-life differential.

Slide 25 · Age and genetics: Clinical clues

Childhood

Mitochondrial defects are described as often manifesting in pediatric patients.

Postpubertal onset

X-linked DCM frequently emerges after puberty or in early adult life.

Any age

Inherited disease remains plausible outside these characteristic patterns.

Slide 26 · Conduction abnormalities may accompany DCM

Congenital conduction abnormalities can coexist with the dilated phenotype.

Robbins relates this association to shared developmental origins of myocytes and conduction elements.

An arrhythmic presentation may precede obvious severe pump failure.

Slide 27 · Myocarditis may evolve into DCM

Sequential endomyocardial biopsy observations support progression from myocarditis to DCM.

Inflammatory myocardial injury can produce a persistent contractile phenotype.

The final dilated morphology may not reveal the initiating myocarditis.

Slide 28 · Viral detection: Supportive, not definitive

Viral genetic material, including Coxsackie B signatures, has been detected in DCM myocardium.

These findings support a possible link between viral myocarditis and later dilation.

Viral detection alone does not establish causality in every individual patient.

Slide 29 · Alcohol-associated myocardial injury

Chronic alcohol exposure

Ethanol / acetaldehyde toxicity

Myocyte injury

Dilated systolic phenotype

Nutritional deficiency may be an additional contributor rather than an exclusive explanation.

Slide 30 · Thiamine deficiency provides a second alcohol-related route

Chronic alcohol use can be associated with inadequate thiamine status.

Thiamine deficiency causes beriberi heart disease, discussed as a form of DCM.

Concurrent direct toxic and nutritional contributions complicate attribution.

Slide 31 · Alcoholic cardiomyopathy has no unique morphology

Dilated chambers, cardiomyocyte remodeling, and fibrosis are shared with other causes.

No specific morphologic feature distinguishing alcohol-associated DCM.

Etiologic attribution requires clinical exposure history rather than histology alone.

Slide 32 · Examples of cardiotoxic exposures

Alcohol

Ethanol / acetaldehyde: Direct toxicity and nutritional contributions.

Cobalt

Heavy-metal exposure has produced DCM in documented contamination settings.

Antineoplastic therapy

Cardiotoxic chemotherapeutic agents, including anthracyclines, are recognized contributors.

Slide 33 · The differential extends beyond obvious toxins

Infection, metabolic disorders, neuromuscular disease, and infiltrative processes among heart-muscle disease associations.

The same source list includes catecholamines, carbon monoxide, and other exposures.

An exposure list is a diagnostic framework—not proof of causality without case evidence.

Slide 34 · Peripartum DCM: Defined clinical window

The Robbins discussion places peripartum cardiomyopathy late in pregnancy or within 5 months postpartum.

The ventricular phenotype may resemble DCM from other causes.

Clinical context is essential because morphology alone cannot determine pregnancy association.

Slide 35 · Potential contributors to peripartum cardiomyopathy

Predisposition

Genetic susceptibility and metabolic vulnerability may lower myocardial resilience.

Hemodynamic conditions

Pregnancy-associated hypertension and volume loading may contribute.

Other influences

Nutritional or subtler biochemical disturbances may participate.

Slide 36 · Experimental antiangiogenic mechanism

SFLT1 / prolactin-derived signals

Excess antiangiogenic activity

Microvascular imbalance

Functional myocardial injury

The specific antiangiogenic pathways are supported principally by mouse models and mechanistic inference.

Slide 37 · Peripartum pathogenesis: Evidence boundaries

Antiangiogenic mediators, including sFLT1 and prolactin cleavage products, in experimental systems.

The proposed mechanism links reduced angiogenesis to microvascular functional ischemic injury.

This is a mechanistic model, not a validated universal explanation for every human case.

Slide 38 · Iron overload can injure the heart

Iron excess can arise from hereditary hemochromatosis or repeated red-cell transfusions.

DCM is described as the most common cardiac manifestation of such iron overload.

The affected myocardium may have dysfunction due to disturbed enzymes and oxidant injury.

Slide 39 · Cardiotoxicity from excess iron

Cardiac iron accumulation

Metal-dependent enzyme disruption

Iron-mediated reactive oxygen species

Myocyte injury / DCM

These are proposed injury routes; The histologic phenotype of established DCM remains nonspecific.

Slide 40 · Supraphysiologic stress pathways

High heart rate

Persistent tachycardia can produce a dilated, hypocontractile phenotype.

Endocrine stimulation

Hyperthyroidism can create excessive cardiac demand.

Adrenergic stimulation

Catecholamine excess, cocaine, or vasopressor exposures can injure myocardium.

Slide 41 · Persistent tachycardia: A remodeling pathway

Sustained tachycardia

Excess mechanical demand

Impaired myocardial function

Dilated cardiomyopathy

Tachycardia should be considered both a trigger for dysfunction and a possible consequence of cardiomyopathy.

Slide 42 · Catecholamine excess has several clinical settings

Pheochromocytoma can expose the heart to high circulating catecholamines.

Cocaine and adrenergic vasopressor agents can produce related effects.

Severe neurologic injury or acute emotional stress may trigger intense autonomic discharge.

Slide 43 · Takotsubo: A stress-associated contractile syndrome

Intense psychological stress may be followed by LV contractile dysfunction.

The LV apex is often affected, producing characteristic apical ballooning.

It in the supraphysiologic-stress discussion; It should not be assumed equivalent to chronic idiopathic DCM.

Slide 44 · How catecholamine stress may impair myocytes

Adrenergic surge

Ca²⁺ overload or focal vasoconstriction

Myocyte stress / ischemic injury

Contractile dysfunction

Uncertainty about the precise mechanism.

Slide 45 · Cardiac dilation: The morphologic centerpiece

RA

LA

RV

LV

RA

LA

RV

LV

Reference configuration

Dilated phenotype

Slide 46 · Gross DCM: Enlarged, heavy, flabby heart

All four chambers can be dilated, and the heart is often markedly enlarged.

Heart weights often two to three times normal.

Hypertrophy may coexist with dilation; Wall thickness alone is not an adequate classifier.

Slide 47 · A striking increase in heart weight

2–3×

The DCM heart may weigh two to three times the expected normal weight.

Increased mass can reflect hypertrophy despite enlarged cavities.

Gross appearance is characteristic but not etiologically specific.

Degrees of enlargement vary across patients.

Slide 48 · Four-chamber dilation: An editable schema

RA

LA

RV

LV

Slide 49 · Stasis can produce intracardiac mural thrombi

RA

LA

RV

LV

Slide 50 · Why mural thrombi form

Poor contractile emptying

Relative intracavitary stasis

Mural thrombus formation

Potential thromboembolism

A cardiac thrombus is a complication of impaired flow, not the initiating lesion in typical DCM.

Slide 51 · Why mitral regurgitation may accompany DCM

Left ventricular dilation

Altered valve geometry

Functional mitral regurgitation

Additional volume burden

The primary pathology is ventricular remodeling; Valvular leaflets need not be intrinsically diseased.

Slide 52 · Gross differential: Exclude primary valve disease

For a primary DCM classification, valve alterations must not themselves explain the myocardial dysfunction.

Associated mitral or tricuspid regurgitation can be secondary to chamber enlargement.

Distinguish a dilated heart caused by chronic primary valvular regurgitation.

Slide 53 · Coronary artery disease remains a critical exclusion

Significant coronary stenosis may generate an ischemic dilated phenotype.

Robbins requires major coronary obstruction to be absent or insufficient to explain the dysfunction in primary DCM.

The ventricular morphology by itself cannot establish a nonischemic etiology.

Slide 54 · Microscopic DCM: Three recurring findings

Myocyte hypertrophy

Many fibers enlarge, with enlarged nuclei.

Attenuated myocytes

Other cells appear stretched, thin, or irregular.

Fibrosis

Variable interstitial and endocardial collagen deposition is common.

Slide 55 · Subendocardial scarring: A proposed explanation

Myocyte hypertrophy

Demand–perfusion imbalance

Subendocardial ischemic injury

Small replacement scars

This as a probable explanation, not a required morphologic progression.

Slide 56 · Microscopy does not identify a unique etiology

Fibrosis, myocyte hypertrophy, and attenuation are morphologically nonspecific.

Neither the extent of changes nor one biopsy field necessarily predicts global pump function.

Histologic abnormalities may not correlate closely with patient prognosis.

Slide 57 · “Ninja-star” nuclei and TTN-related DCM

≥5%

Markedly distorted, hyperchromatic nuclei in this proportion of myocytes are described as highly suggestive.

The finding is specifically associated with titin-truncating mutation cases.

Morphologic association is not a substitute for genetic confirmation.

The marker must not be generalized to all DCM phenotypes.

Slide 58 · DCM presents across the lifespan

DCM can present in childhood and adulthood.

Presentation most often between 20 and 50 years of age.

Clinical timing can guide etiologic investigation without proving a particular mechanism.

Slide 59 · Pump failure explains progressive symptoms

Ineffective LV contraction

Reduced cardiac performance

Congestive physiology

Dyspnea / fatigue / exercise intolerance

The dominant clinical syndrome is slowly progressive congestive heart failure.

Slide 60 · Clinical consequences of advanced DCM

Heart failure

Dyspnea, poor exertional capacity, fatigue, and ongoing pump dysfunction.

Arrhythmias

Abnormal rhythm is frequent and contributes to morbidity and sudden death.

Embolic disease

Mural thrombi may embolize to the systemic circulation.

Slide 61 · Rhythm disturbances can be life-threatening

Abnormal cardiac rhythms are common in the setting of DCM.

Progressive pump failure and arrhythmias are leading modes of death account.

Underlying structural or genetic disease can influence arrhythmia susceptibility.

Slide 62 · The pathology–outcome relationship is imperfect

Gross enlargement and fibrosis provide evidence of remodeling but do not specify prognosis on their own.

Contractile impairment and clinical consequences define functional severity.

The evaluation must integrate etiology, function, complications, and response to therapy.

Slide 63 · Patterns that distinguish DCM from its mimics

Pattern

Dominant functional defect

Characteristic morphology

Dilated cardiomyopathy

Systolic dysfunction

Large chambers; Hypertrophy may coexist.

Hypertrophic cardiomyopathy

Diastolic filling dysfunction

Thick ventricular myocardium; Often no dilation.

Restrictive cardiomyopathy

Impaired diastolic filling

Nondilated ventricles; Atrial dilation common.

Ischemic / valvular disease

May also impair systole

Identify causal coronary or valve abnormality.

Slide 64 · Therapeutic implications noted by Robbins

Pharmacologic heart failure treatment may produce substantial clinical improvement in selected patients.

Electrical resynchronization by biventricular pacing can benefit appropriately selected patients.

These interventions address functional consequences but do not make the underlying etiology uniform.

Slide 65 · Advanced support options

Cardiac transplantation is an option in suitable patients with refractory end-stage failure.

Long-term ventricular assist devices can support circulation.

In some patients, shorter-term mechanical support permits durable improvement in cardiac function.

Slide 66 · Case: A dilated heart with mitral regurgitation

Illustrative vignette

An adult develops progressive exertional dyspnea. Imaging shows an enlarged, globally hypocontractile left ventricle and mitral regurgitation without primary mitral leaflet damage.

What causal sequence explains the regurgitation?

Slide 67 · Case reasoning: Secondary mitral regurgitation

Intrinsic myocardial injury

LV cavity expansion

Functional valve incompetence

Worsened volume loading

The valve leak is a consequence of altered ventricular geometry, not necessarily primary valve pathology.

Slide 68 · Case: Etiologic classification

Illustrative vignette

A patient with ventricular dilation, poor contractility, and mural thrombus also has severe coronary obstruction and a history of large myocardial infarctions.

Why is “primary idiopathic DCM” not yet justified?

Slide 69 · Case reasoning: A phenotype is not an etiology

Dilated systolic failure may arise from ischemic myocardial disease.

Significant coronary disease sufficient to explain dysfunction favors an ischemic cause.

Primary DCM is considered after competing explanations are excluded.

Slide 70 · Case: A familial presentation

Illustrative vignette

Two relatives have a dilated, poorly contracting heart. Another older relative has no cardiac symptoms. A pathogenic TTN truncating variant is under investigation.

Which genetic concepts prevent overinterpretation of the pedigree?

Slide 71 · Case reasoning: Penetrance and molecular interpretation

Variable penetrance means unaffected relatives do not necessarily exclude inherited disease.

TTN truncating variants are an important association, but any candidate variant needs context.

Family history, phenotype, and molecular data should be assessed together.

Slide 72 · High-yield synthesis: The DCM phenotype

Intrinsic myocyte dysfunction culminates in chamber dilation and impaired systolic contraction.

Inherited and acquired pathways may produce the same gross and microscopic appearance.

Fibrosis and hypertrophy are common but not diagnostic of a specific etiology.

Clinical hazards include failure, arrhythmias, functional regurgitation, and thromboembolism.

Slide 73 · Three points to retain

DCM is a functional–morphologic syndrome; Seek an explanation rather than assuming idiopathic disease.

TTN, other structural genes, myocarditis, toxins, peripartum factors, iron, and stress all merit etiologic consideration.

Chamber dilation explains secondary valve incompetence and thrombogenic blood stasis.

Slide 74 · Self-check: Clinical-pathologic reasoning

Question

Answer

Reason

What dominates functionally?

Systolic dysfunction

Contractile failure with chamber dilation.

Why can thromboembolism occur?

Intracavitary blood stasis

Reduced emptying favors mural thrombi.

Does fibrosis identify the cause?

No

Histologic changes are nonspecific.

Does MR require primary valve pathology?

No

Dilation can produce functional regurgitation.

Slide 75 · Integrating the DCM phenotype

The combination of chamber dilation and impaired contraction requires an etiologic explanation.

Inherited and acquired mechanisms can converge on similar gross and microscopic pathology.

Fibrosis, hypertrophy, and stasis-related thrombi contribute to morphologic interpretation.

Clinical assessment must address pump failure, arrhythmias, and embolic risk.